We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.

Delisted

INFI was delisted on the 13th of September, 2023.

129 hedge funds and large institutions have $1.56B invested in Infinity Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 45 increasing their positions, 50 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more capital invested

Capital invested by funds: $556M → $1.56B (+$1B)

62% more call options, than puts

Call options by funds: $6.52M | Put options by funds: $4.03M

6% less funds holding

Funds holding: 137129 (-8)

10% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 50

29% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 24

Holders
129
Holders Change
-8
Holders Change %
-5.84%
% of All Funds
3.6%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
45
Reduced
50
Closed
24
Calls
$6.52M
Puts
$4.03M
Net Calls
+$2.49M
Net Calls Change
+$2.01M
Name Holding Trade Value Shares
Change
Change in
Stake
CWG
76
C WorldWide Group
Denmark
$344K +$375K +40,680 New
Morgan Stanley
77
Morgan Stanley
New York
$341K -$1.24M -134,731 -77%
AFG
78
American Financial Group
Ohio
$338K
Citadel Advisors
79
Citadel Advisors
Florida
$330K +$361K +39,100 New
William Blair & Company
80
William Blair & Company
Illinois
$311K -$105K -11,385 -24%
SCA
81
Secor Capital Advisors
New York
$308K +$26.4K +2,857 +9%
MLICM
82
Metropolitan Life Insurance Company (MetLife)
New York
$302K -$4.7K -509 -1%
Barclays
83
Barclays
United Kingdom
$282K +$225K +24,347 +222%
CSS
84
Cubist Systematic Strategies
Connecticut
$266K +$149K +16,171 +105%
Nomura Holdings
85
Nomura Holdings
Japan
$264K +$44K +4,773 +18%
SCM
86
Stevens Capital Management
Pennsylvania
$262K +$132K +14,283 +85%
SM
87
Sabby Management
Florida
$254K +$277K +30,000 New
AIG
88
American International Group
New York
$243K +$314 +34 +0.1%
SKK
89
Shepherd Kaplan Krochuk
Massachusetts
$228K +$249K +27,031 New
Group One Trading
90
Group One Trading
Illinois
$218K -$67.9K -7,365 -22%
UBS AM
91
UBS AM
Illinois
$212K
AQR Capital Management
92
AQR Capital Management
Connecticut
$211K -$262K -28,364 -53%
DekaBank Deutsche Girozentrale
93
DekaBank Deutsche Girozentrale
Germany
$210K +$9.22K +1,000 +4%
VOYA Investment Management
94
VOYA Investment Management
Georgia
$207K -$58.9K -6,383 -21%
GIA
95
Gargoyle Investment Advisor
New Jersey
$199K
Jacobs Levy Equity Management
96
Jacobs Levy Equity Management
New Jersey
$185K -$315K -34,100 -61%
EMG
97
Ellington Management Group
Connecticut
$183K -$46.5K -5,036 -19%
Tudor Investment Corp
98
Tudor Investment Corp
Connecticut
$183K +$24.9K +2,700 +14%
Asset Management One
99
Asset Management One
Japan
$178K
PA
100
Perceptive Advisors
New York
$169K -$194K -21,000 -51%

INFI Hedge Fund Activity: Q3 2015 in Review

129 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2015, worth a combined $1.56B — up 180% from $556M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of INFI and 17 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 45 added.

The largest buyer was Deerfield Management, adding an estimated $13.3M. The largest seller was Numeric Investors, cutting an estimated $8.25M.

  • 129 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2015, down from 137 in Q2 2015.
  • Funds reported $1.56B of Infinity Pharmaceuticals, Inc. stock for Q3 2015, up 180% quarter-over-quarter.
  • 17 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2015 and 24 closed out, a net change of -7 holders.
  • The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2015 was Deerfield Management, an estimated $13.3M added.
  • The largest Infinity Pharmaceuticals, Inc. seller in Q3 2015 was Numeric Investors, an estimated $8.25M sold.

Based on aggregated 13F filings for Q3 2015.